Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.52 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.50 |
| ▸ | ITGAV | P06756 | 1/20 | 0.50 |
| ▸ | CTSL | P07711 | 11/20 | 0.49 |
| ▸ | CTSB | P07858 | 5/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2861823 | 1.00 | TGM2 (0.55) | TGM2HDAC1HDAC2ITGB3ITGAV | |
| SCHEMBL6987072 | 0.95 | TGM2 (0.52) | TGM2HDAC1HDAC2ITGB3ITGAV | |
| SCHEMBL6544456 | 0.95 | TGM2 (0.52) | TGM2HDAC1HDAC2ITGB3ITGAV | |
| SCHEMBL2867696 | 0.82 | PPARA (0.51) | TGM2HDAC1ITGB3ITGAV | |
| SCHEMBL2867690 | 0.82 | PPARA (0.51) | TGM2HDAC1ITGB3ITGAV | |
| SCHEMBL29027530 | 0.79 | TGM2 (0.62) | TGM2HDAC1HDAC2ITGB3ITGAV | |
| SCHEMBL29027528 | 0.79 | TGM2 (0.62) | TGM2HDAC1HDAC2ITGB3ITGAV | |
| SCHEMBL11100666 | 0.77 | TGM2 (0.60) | TGM2HDAC1HDAC2CTSLCTSB | |
| SCHEMBL3625155 | 0.77 | MMP2 (0.62) | TGM2HDAC1HDAC2CTSL | |
| SCHEMBL11145406 | 0.77 | TGM2 (0.68) | TGM2HDAC1HDAC2CTSLSIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750162-B2 | Process for preparation of nonnatural amino acid and intermediate thereof | DAISO CO., LTD. (JP) | 2010-07-06 | — | — | US | disclosed |
| US-20070208180-A1 | Process for Preparation of Nonnatural Amino Acid and Intermediate Thereof | DAISO CO., LTD. (JP) | 2007-09-06 | — | — | US | disclosed |
| EP-1739077-A1 | PROCESS FOR PRODUCTION OF NONNATURAL AMINO ACIDS AND INTERMEDIATES THEREFOR | DAISO CO., LTD. (JP) | 2007-01-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208180-A1 | Process for Preparation of Nonnatural Amino Acid and Intermediate Thereof | BCAT1, BCAT2, AADAT | TGM2 2492/4885HDAC1 4145/4885HDAC2 4153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.